Buy Ara-290 Peptide online – at Peptira

ARA-290 Peptide Research

ARA-290 Peptide, also known as cibinetide, is a synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO). Unlike full-length erythropoietin, ARA-290 was designed as a non-erythropoietic peptide for research into tissue-protective signaling and the innate repair receptor.

ARA-290 peptide has been investigated in preclinical and human research involving cellular signaling, nerve biology, inflammation-related pathways, and metabolic research.

Research Material for Laboratory Applications

ARA-290 peptide is intended for qualified laboratory and analytical research involving peptide chemistry, receptor biology, cellular signaling, and experimental neurobiology.

Researchers can investigate ARA-290 under controlled conditions to examine its molecular characteristics, receptor interactions, biological activity, and potential effects within specific experimental models.

The 10MG designation identifies the quantity of research material supplied and should not be interpreted as a human dosage or administration recommendation.

Innate Repair Receptor Research

A major area of ARA-290 research involves the innate repair receptor, a receptor complex associated with erythropoietin receptor biology and the CD131 subunit. Research has investigated how ARA-290 interacts with this receptor system without the classical erythropoietic activity associated with full-length EPO.

This makes ARA-290 relevant to laboratory studies examining receptor signaling, cellular responses, and mechanisms associated with tissue stress and repair.

Neurobiology Research

Preclinical research has investigated ARA-290 in experimental models involving nerve injury and neuropathic pain. In a rat nerve-injury model, researchers observed dose-dependent changes in mechanical and cold allodynia together with changes in spinal microglial responses. These findings represent animal-model research and should not be interpreted as proof of human therapeutic effectiveness.

Human research has also investigated ARA-290 in small clinical studies involving conditions such as type 2 diabetes with painful neuropathy. These studies provide research data but do not establish ARA-290 as an approved medical treatment.

Metabolic and Cellular Research

ARA-290 has been studied in experimental research involving metabolic control and cellular responses. A published Phase 2 study investigated ARA-290 in people with type 2 diabetes and reported changes in selected metabolic and neuropathy-related measures over the study period.

These findings should be considered within the specific design and limitations of the study rather than as evidence of an established clinical indication.

Laboratory Research Applications

ARA-290 may be relevant to qualified laboratory investigations involving:

• Innate repair receptor signaling
• EPO-derived peptide research
• Cellular signaling
• Neurobiology research
• Nerve-cell and small-fibre research
• Inflammation-related pathways
• Peptide-receptor interactions
• Molecular pharmacology
• Analytical peptide characterization

Research outcomes can vary according to the experimental model, peptide formulation, concentration, analytical method, and study conditions.

ARA-290 and Erythropoietin

ARA-290 is derived from a region of erythropoietin but is not the same molecule as full-length EPO. It is an 11-residue peptide designed for investigation of receptor signaling separate from the classical red-blood-cell-producing activity of erythropoietin.

For research applications, the exact identity, sequence, formulation, purity, and analytical specifications of the material should be verified using the applicable certificate of analysis.

Regulatory and Research Context

ARA-290 remains an investigational research compound and is not an FDA-approved medicine. Published human studies have investigated the compound, including randomized controlled research, but these studies do not establish regulatory approval or make a particular research-grade product suitable for human administration.

Accordingly, ARA-290 10MG should be presented as research material rather than as an approved medication or treatment.

Laboratory Research Use Only

ARA-290 peptide is offered strictly for qualified scientific and analytical research. It is not marketed as a medication, dietary supplement, or treatment and is not intended for human or veterinary use.

Researchers should handle, store, characterize, and analyze ARA-290 according to appropriate institutional laboratory procedures, applicable safety requirements, and validated analytical protocols.

Important Research Notice

ARA-290 peptide is intended exclusively for scientific research and analytical purposes. Published experimental findings should not be interpreted as a claim that ARA-290 diagnoses, treats, prevents, or cures any disease or medical condition. Research outcomes may vary according to the model, formulation, concentration, and experimental methodology.